A PHASE 3, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF CARBAVANCE (MEROPENEM/RPX7009) VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH SELECTED SERIOUS INFECTIONS DUE TO CARBAPENEM-RESISTANT ENTEROBACTERIACEAE

Trial Profile

A PHASE 3, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF CARBAVANCE (MEROPENEM/RPX7009) VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH SELECTED SERIOUS INFECTIONS DUE TO CARBAPENEM-RESISTANT ENTEROBACTERIACEAE

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Meropenem/vaborbactam (Primary)
  • Indications Enterobacteriaceae infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 28 Jan 2016 Status changed from active, no longer recruiting to recruiting, as reported by United Kingdom Clinical Research Network.
    • 18 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top